{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:33:56Z","timestamp":1759336436366},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,18]]},"DOI":"10.7759\/cureus.50717","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T12:03:41Z","timestamp":1702901021000},"source":"Crossref","is-referenced-by-count":1,"title":["Delayed Hemolytic Transfusion Reaction With Hyperhemolysis Syndrome Due to Anti-M Alloantibody in Myelofibrosis: A Case Report"],"prefix":"10.7759","author":[{"given":"Mohammad S","family":"Alsoreeky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laith K","family":"Lutfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad  A","family":"Altamimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamer H","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mashael S","family":"Khalayleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad S","family":"Alkader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.6436-20","article-title":"Fatal disseminated tuberculosis and concurrent disseminated cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis: a case report and literature review","volume":"61","author":"Ogai A","year":"2022","unstructured":"Ogai A, Yagi K, Ito F, Domoto H, Shiomi T, Chin K. Fatal disseminated tuberculosis and concurrent disseminated cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis: a case report and literature review. Intern Med. 2022, 61:1271-8. 10.2169\/internalmedicine.6436-20","journal-title":"Intern Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024567","article-title":"Acute promyelocytic leukemia with myelofibrosis: a case report and literature review","volume":"100","author":"Xiao M","year":"2021","unstructured":"Xiao M, Qin L, Niu X, et al.. Acute promyelocytic leukemia with myelofibrosis: a case report and literature review. Medicine (Baltimore). 2021, 100:e24567. 10.1097\/MD.0000000000024567","journal-title":"Medicine (Baltimore)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/genes12081271","article-title":"Clinical relevance of VEGFA (rs3025039) +936 C>T polymorphism in primary myelofibrosis: susceptibility, clinical co-variates, and outcomes","volume":"12","author":"Villani L","year":"2021","unstructured":"Villani L, Carolei A, Rosti V, et al.. Clinical relevance of VEGFA (rs3025039) +936 C>T polymorphism in primary myelofibrosis: susceptibility, clinical co-variates, and outcomes. Genes (Basel). 2021, 12:1271. 10.3390\/genes12081271","journal-title":"Genes (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.14740\/jh968","article-title":"An unusual case of delayed hemolytic transfusion reaction with hyperhemolysis syndrome due to anti-Jk(b) and anti-Fy(a) alloantibodies","volume":"11","author":"El Alaoui K","year":"2022","unstructured":"El Alaoui K, Benghiat FS, Colard M. An unusual case of delayed hemolytic transfusion reaction with hyperhemolysis syndrome due to anti-Jk(b) and anti-Fy(a) alloantibodies. J Hematol. 2022, 11:66-70. 10.14740\/jh968","journal-title":"J Hematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.13017","article-title":"Hyperhemolysis syndrome in a patient with sickle cell disease and acute chest syndrome","volume":"13","author":"Shankar K","year":"2021","unstructured":"Shankar K, Shah D, Huffman DL, Peterson C, Bhagavatula R. Hyperhemolysis syndrome in a patient with sickle cell disease and acute chest syndrome. Cureus. 2021, 13:e13017. 10.7759\/cureus.13017","journal-title":"Cureus"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/hematolrep14030032","article-title":"Acute hyperhemolysis syndrome in a patient with known sickle cell anemia refractory to steroids and IVIG treated with tocilizumab and erythropoietin: a case report and review of literature","volume":"14","author":"Menakuru SR","year":"2022","unstructured":"Menakuru SR, Priscu A, Dhillon V, Salih A. Acute hyperhemolysis syndrome in a patient with known sickle cell anemia refractory to steroids and IVIG treated with tocilizumab and erythropoietin: a case report and review of literature. Hematol Rep. 2022, 14:235-9. 10.3390\/hematolrep14030032","journal-title":"Hematol Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.4226","article-title":"Post-transfusion hyperhemolysis syndrome in a patient with beta thalassemia major","volume":"9","author":"Kasinathan G","year":"2021","unstructured":"Kasinathan G, Sathar J. Post-transfusion hyperhemolysis syndrome in a patient with beta thalassemia major. Clin Case Rep. 2021, 9:e04226. 10.1002\/ccr3.4226","journal-title":"Clin Case Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15198","article-title":"Anti-N and anti-Do(a) immunoglobulin\u2009G alloantibody-mediated delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease treated with eculizumab and HBOC-201: case report and review of the literature","volume":"59","author":"Unnikrishnan A","year":"2019","unstructured":"Unnikrishnan A, Pelletier JP, Bari S, et al.. Anti-N and anti-Do(a) immunoglobulin\u2009G alloantibody-mediated delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease treated with eculizumab and HBOC-201: case report and review of the literature. Transfusion. 2019, 59:1907-10. 10.1111\/trf.15198","journal-title":"Transfusion"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01157-4","article-title":"Momelotinib: an emerging treatment for myelofibrosis patients with anemia","volume":"15","author":"Chifotides HT","year":"2022","unstructured":"Chifotides HT, Bose P, Verstovsek S. Momelotinib: an emerging treatment for myelofibrosis patients with anemia. J Hematol Oncol. 2022, 15:7. 10.1186\/s13045-021-01157-4","journal-title":"J Hematol Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2022000340","article-title":"New approaches to tackle cytopenic myelofibrosis","volume":"2022","author":"Reynolds SB","year":"2022","unstructured":"Reynolds SB, Pettit K. New approaches to tackle cytopenic myelofibrosis. Hematology Am Soc Hematol Educ Program. 2022, 2022:235-44. 10.1182\/hematology.2022000340","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159\/000512945","article-title":"Hyperhaemolytic syndrome in sickle cell disease: clearing the cobwebs","volume":"30","author":"Madu AJ","year":"2021","unstructured":"Madu AJ, Ugwu AO, Efobi C. Hyperhaemolytic syndrome in sickle cell disease: clearing the cobwebs. Med Princ Pract. 2021, 30:236-43. 10.1159\/000512945","journal-title":"Med Princ Pract"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29070395","article-title":"Management of myelofibrosis during treatment with ruxolitinib: a real-world perspective in case of resistance and\/or intolerance","volume":"29","author":"Breccia M","year":"2022","unstructured":"Breccia M, Palandri F, Guglielmelli P, et al.. Management of myelofibrosis during treatment with ruxolitinib: a real-world perspective in case of resistance and\/or intolerance. Curr Oncol. 2022, 29:4970-80. 10.3390\/curroncol29070395","journal-title":"Curr Oncol"},{"key":"ref13","article-title":"Splenectomy","author":"Yi SL","year":"2023","unstructured":"Yi SL, Lopez JL. Splenectomy. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.14991","article-title":"Recurrent hyperhemolysis syndrome in sickle cell disease","volume":"13","author":"Rehman R","year":"2021","unstructured":"Rehman R, Saadat SB, Tran DH, Constantinescu S, Qamruzzaman Y. Recurrent hyperhemolysis syndrome in sickle cell disease. Cureus. 2021, 13:e14991. 10.7759\/cureus.14991","journal-title":"Cureus"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17302","article-title":"Successful treatment with plasma exchange in life-threatening hyperhemolytic syndrome unrelated to sickle cell disease","volume":"63","author":"Shaulov A","year":"2023","unstructured":"Shaulov A, Rund D, Filon D, Nachmias B, Khalili A, Manny N, Zelig O. Successful treatment with plasma exchange in life-threatening hyperhemolytic syndrome unrelated to sickle cell disease. Transfusion. 2023, 63:1100-6. 10.1111\/trf.17302","journal-title":"Transfusion"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/204461-delayed-hemolytic-transfusion-reaction-with-hyperhemolysis-syndrome-due-to-anti-m-alloantibody-in-myelofibrosis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:10:04Z","timestamp":1707509404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/204461-delayed-hemolytic-transfusion-reaction-with-hyperhemolysis-syndrome-due-to-anti-m-alloantibody-in-myelofibrosis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,18]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.50717","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,18]]}}}